A Targeted Therapy Combination for Colorectal Cancer
The FDA has approved a new combination of molecularly targeted therapeutics for treating metastatic colorectal cancer with a BRAF V600E gene mutation.
Progress Against Cancer
The FDA has approved a new combination of molecularly targeted therapeutics for treating metastatic colorectal cancer with a BRAF V600E gene mutation.
CAR-T cell therapy may help patients after a relapse of mantle cell lymphoma, and more news of the week from Cancer Today.
People being treated for cancer may be at elevated risk of developing severe cases of COVID-19. The coronavirus is also affecting how cancer care is delivered. A column by the editor-in-chief of Cancer Today William G. Nelson, MD, PhD, director of the Johns Hopkins Kimmel Cancer Center in Baltimore.
The FDA has approved a new combination of immunotherapy and chemotherapy as an initial treatment for extensive-stage small cell lung cancer.
Cancer centers are taking advantage of their in-house molecular laboratories to selectively test certain cancer patients for the coronavirus.
Cancer patients and survivors share tips on how to respond to the coronavirus pandemic, and more news of the week from Cancer Today.
The world is facing a pandemic unlike any in living memory. For our cancer research community, the novel coronavirus epidemic evokes memories of the 2003 outbreak of Severe Acute Respiratory Syndrome (SARS), which had far-reaching effects including the rescheduling of American Association for Cancer Research (AACR) Annual Meeting. Yet the total reported caseload of SARS was approximately 8,000, with 774 deaths; only 29 cases were identified in the United States.
Cancer centers are making changes to care for some patients enrolled in trials.
Pancreatic cancer remains a difficult disease to treat and is expected to be the second leading cause of U.S. cancer-related deaths by 2030.
A gene-editing tool called CRISPR holds promise for treating cancer. What does the new technology mean for patients?
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More